Hyaluronidase Injection, Solution
NDC Package 51662-1555-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Hyaluronidase injection is 1.1 Subcutaneous Fluid AdministrationHYLENEX recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration.1.2 Dispersion and Absorption of Injected DrugsHYLENEX recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.1.3 Subcutaneous UrographyHYLENEX recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1555 and is authorized under FDA application BLA021859.

Identification & Billing

NDC Package Code
51662-1555-1
Package Description
1 VIAL in 1 BOX / 1 mL in 1 VIAL
Product Code
51662-1555
11-Digit Billing Format
51662155501
RxNorm Crosswalk
  • RxCUI: 630936 - hyaluronidase, human recombinant 150 UNT in 1 ML Injection
  • RxCUI: 630936 - 1 ML hyaluronidase, human recombinant 150 UNT/ML Injection
  • RxCUI: 630936 - hyaluronidase, human recombinant 150 UNT per 1 ML Injection
  • RxCUI: 630939 - Hylenex 150 UNT in 1 ML Injection
  • RxCUI: 630939 - 1 ML hyaluronidase, human recombinant 150 UNT/ML Injection [Hylenex]

Clinical Specifications

Proprietary Name
Hyaluronidase
Non-Proprietary Name
Hyaluronidase
Substance Name
Hyaluronidase (human Recombinant)
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
HYALURONIDASE (HUMAN RECOMBINANT) 150 [USP'U]/mL
Pharmacologic Class
Usage Information
1.1 Subcutaneous Fluid AdministrationHYLENEX recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration.1.2 Dispersion and Absorption of Injected DrugsHYLENEX recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.1.3 Subcutaneous UrographyHYLENEX recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
Product Type
Human Prescription Drug
FDA Application #
BLA021859
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
06-04-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J3473
Source: ASP
Hyaluronidase recombinant
HCPCS Dosage 1 USP UNIT
Units / Pkg 150

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1555-1 identifies a specific commercial package of 1 vial in 1 box / 1 ml in 1 vial of Hyaluronidase, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection, solution is formulated for subcutaneous use and contains hyaluronidase (human recombinant) as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on June 04, 2021. The current certification is valid through December 31, 2026.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662155501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1555-1
11-Digit CMS (5-4-2)
51662-1555-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.